The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
Jackson S, Baker EH, Gross AM, Whitcomb P, Baldwin A, Derdak J, Tibery C, Desanto J, Carbonell A, Yohay K, O'Sullivan G, Chen AP, Widemann BC, Dombi E.
Jackson S, et al. Among authors: baker eh.
Neurooncol Adv. 2020 Aug 8;2(1):vdaa095. doi: 10.1093/noajnl/vdaa095. eCollection 2020 Jan-Dec.
Neurooncol Adv. 2020.
PMID: 32939452
Free PMC article.